[go: up one dir, main page]

Rubinstein et al., 2009 - Google Patents

Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo

Rubinstein et al., 2009

View PDF
Document ID
17013311871879360277
Author
Rubinstein M
Salem M
Kadima A
Nguyen C
Gillanders W
Nishimura M
Cole D
Publication year
Publication venue
Cancer gene therapy

External Links

Snippet

Adoptive T-cell therapy is clinically efficacious in the treatment of select cancers. However, it is often difficult to obtain adequate numbers of tumor-specific T cells for therapy. One method for overcoming this limitation is to generate tumor-specific T cells by retrovirally mediated T …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material Not used, see subgroups
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Similar Documents

Publication Publication Date Title
AU2021203481B2 (en) Chimeric antigen receptors (CARs), compositions and methods of use thereof
Hikosaka et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator
Singh et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system
Peng et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity
EP3500593B1 (en) T cell receptors and immune therapy using the same
JP2024147602A (en) Methods for producing cells expressing recombinant receptors and related compositions
EP3215534B1 (en) Chimeric antigen receptors (car) to selectively target protein complexes
US11299552B2 (en) Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy
JP2022017256A (en) Chimeric antigen receptor and its use
CN111247242A (en) Chimeric Antigen Receptors (CARs), compositions and methods of use thereof
CN115960204B (en) KRAS_G12V mutant antigen-specific TCR and its co-expression with CD8 redirect CD4 T cells
KR20210013691A (en) Chimeric antigen receptor with modified linker domain and uses thereof
Daniel‐Meshulam et al. Enhanced antitumor activity mediated by human 4‐1BB‐engineered T cells
Duong et al. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer
JP2023182711A (en) Methods, compositions and components for CRISPR-CAS9 editing of CBLB in T cells for immunotherapy
Chakravarti et al. Inducible gene switches with memory in human T cells for cellular immunotherapy
US20250241849A1 (en) Compositions and methods for treating immunological dysfunction
CN115335087A (en) Compositions and methods for reducing transplant rejection in allogeneic cell therapy
Hanson et al. CD62L expression marks a functionally distinct subset of memory B cells
JP2023554674A (en) Peptide marker for tracking genetically modified cells
TW202237823A (en) Compositions and methods for the treatment of cancer using a tgfβrii engineered t cell therapy
KR20210120019A (en) Cell-specific transcriptional regulatory sequences and uses thereof
Rubinstein et al. Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo
Eguren-Santamaria et al. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic
Hoseini et al. Inducible T-cell receptor expression in precursor T cells for leukemia control